Porte R J, Bontempo F A, Knot E A, Lewis J H, Kang Y G, Starzl T E
Department of Medicine, University of Pittsburgh, Pennsylvania.
Transplantation. 1989 Jun;47(6):978-84. doi: 10.1097/00007890-198906000-00012.
Orthotopic liver transplantation is frequently associated with hyperfibrinolysis, the origin and clinical relevance of which is largely unknown. In 20 orthotopic liver transplantations, we studied the occurrence and systemic effects of hyperfibrinolysis. Severe fibrinolysis was defined to be present when the euglobulin-clot lysis time and the whole-blood-clot lysis time, as measured by thrombelastography, were shorter than 60 and 90 min, respectively, at some time during the operation. Based on these criteria, 7 patients had minimal fibrinolysis (group I), and 13 patients had severe fibrinolysis (group II). In group II a gradual increase of tissue-type plasminogen activator (t-PA) activity was seen during the anhepatic stage, followed by an "explosive" increase immediately after graft reperfusion (P = 0.0004, compared with group I), and a reduction of plasminogen activator inhibitor (PAI) activity. Plasma degradation products of fibrinogen and fibrin increased parallel to t-PA activity, and levels were significantly higher at 45 min after graft reperfusion in group II compared with group I (P less than 0.04). Thrombin-antithrombin III complexes showed an identical steady increase in both groups, indicating that increased t-PA activity was not related to thrombin formation. A combination of increased endothelial release and reduced hepatic clearance may have caused the increased t-PA activity. The t-PA-associated destruction of fibrinogen and fibrin after graft reperfusion is consistent with the clinical signs of severe oozing often seen in this period. These observations may have important clinical implications for the treatment of bleeding in patients undergoing orthotopic liver transplantation.
原位肝移植常伴有高纤溶状态,但其起源及临床相关性在很大程度上尚不清楚。在20例原位肝移植中,我们研究了高纤溶状态的发生情况及其全身影响。当通过血栓弹力图测量的优球蛋白凝块溶解时间和全血凝块溶解时间在手术过程中的某些时间分别短于60分钟和90分钟时,定义为存在严重纤溶。根据这些标准,7例患者纤溶轻微(I组),13例患者纤溶严重(II组)。在II组中,无肝期组织型纤溶酶原激活物(t-PA)活性逐渐升高,随后在移植肝再灌注后立即“爆发性”升高(与I组相比,P = 0.0004),同时纤溶酶原激活物抑制剂(PAI)活性降低。纤维蛋白原和纤维蛋白的血浆降解产物与t-PA活性平行增加,II组在移植肝再灌注后45分钟时的水平显著高于I组(P < 0.04)。两组中凝血酶 - 抗凝血酶III复合物均呈相同的稳定升高,表明t-PA活性增加与凝血酶形成无关。内皮释放增加和肝脏清除减少的共同作用可能导致了t-PA活性增加。移植肝再灌注后t-PA相关的纤维蛋白原和纤维蛋白破坏与该时期常见的严重渗血的临床体征相符。这些观察结果可能对原位肝移植患者出血的治疗具有重要的临床意义。